Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IgE multiple myeloma.

M Macro1, I André, E Comby

  • 1Department of Clinical Haematology, Centre Hospitalier Universitaire, Caen, France.

Leukemia & Lymphoma
|February 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort.

Clinical lymphoma, myeloma & leukemia·2024
Same author

Teclistamab for relapsed refractory multiple myeloma patients on dialysis.

British journal of haematology·2024
Same author

An engineered enzyme embedded into PLA to make self-biodegradable plastic.

Nature·2024
Same author

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.

Annals of hematology·2023
Same author

Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial.

Leukemia research·2023
Same author

Author Correction to: T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all.

Cellular & molecular immunology·2022
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

IgE multiple myeloma, a rare plasma cell disorder, was observed in a 70-year-old woman with a sacral plasmacytoma. Treatment involved surgery, chemotherapy, radiotherapy, and bisphosphonates, leading to a sustained partial response.

Area of Science:

  • Hematology
  • Oncology

Background:

  • IgE multiple myeloma is a rare plasma cell neoplasm.
  • Characterized by high rates of Bence-Jones proteinuria and plasma cell leukemia.

Observation:

  • A case of stage III IgE kappa multiple myeloma presenting as a sacral plasmacytoma in a 70-year-old female.
  • Elevated serum IgE levels without symptoms of hyper-IgE syndrome or mast cell activation.

Findings:

  • Tumoral plasma cells confirmed to produce IgE kappa.
  • Successful management with surgical tumor resection, melphalan-prednisone chemotherapy, radiotherapy, and bisphosphonate therapy.
  • Achieved a partial response with a plateau phase and improved bone mineral content after 1 year, sustained over 28 months.

Implications:

Related Experiment Videos

  • Highlights the importance of considering IgE myeloma in rare plasma cell disorders.
  • Demonstrates the efficacy of a multimodal treatment approach for managing complex myeloma cases.
  • Emphasizes the role of bisphosphonates in addressing myeloma-related bone disease.